Developer docs
API playgroundTry for free, no card

Search company profiles

Pathios Therapeutics

Full company profile

uuid0000m97

Namestring
Pathios Therapeutics
Legal namestring
Pathios Therapeutics Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Pathios Therapeutics is a clinical-stage oncology and immunology company founded in 2017 and headquartered at Milton Park, Oxford, UK. The company develops first-in-class small molecule inhibitors of GPR65, an acid-sensing G protein-coupled receptor that drives immunosuppressive polarization of immune cells in the acidic tumour microenvironment. Its lead asset, PTT-4256, is an orally bioavailable, highly selective GPR65 inhibitor (IC50 < 1 nM in human macrophages, >500-fold selectivity over related receptors) that is being evaluated in the RAISIC-1 Phase 1/2 study in patients with advanced solid tumours in Australia, with first patient dosed in November 2024. The company also pursues CNS-penetrating GPR65 inhibitors for malignant brain tumours and is exploring neurodegenerative indications (Alzheimer's, vascular dementia, Parkinson's) supported by human genetic validation linking GPR65 coding variants to disease.

The company's core technology rests on human-genetics-led target validation (notably the GPR65 I231L coding variant, rs3742704) combined with proprietary small molecule chemistry and a partnership with Sygnature Discovery for GPCR medicinal chemistry. Pathios operates within the Molecule to Medicine (MTM) incubator ecosystem alongside sister companies ThirtyFiveBio, Grey Wolf Therapeutics, Melio Bio, Lucia Bio and Curlew Bio, sharing operational and bioinformatics infrastructure.

Pathios' business model is a licensing-and-partnership biotech model: it advances candidates through clinical proof-of-concept and intends to out-license or co-develop with a major pharmaceutical company for global commercialization. The company has raised approximately US$58M to date, including a $25M Series B in April 2024 that brought in Bristol Myers Squibb as a strategic investor alongside Canaan and Brandon Capital. It is pre-revenue with no commercial products, a sub-10-person team (per firmographic data), and primarily uses scientific conferences (AACR, SITC, ESMO, ASCO) and peer-reviewed publications as its marketing channels ahead of a future partnership transaction.

Short descriptiontext

Pathios Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule inhibitors of the acid-sensing GPCR GPR65 to reverse immunosuppression in solid tumours, with lead asset PTT-4256 in Phase 1/2 trials for advanced solid cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilton, United Kingdom
HQ citystring
Milton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, small molecule therapeutics, GPCR drug discovery, immuno-oncology research, clinical-stage biotechnology
Industry1 code
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cancer Immunotherapy / Immuno-Oncology Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical licensing and partnership
TypeLicensing Royalties
Description

As a clinical-stage biotech, Pathios' revenue model centers on developing novel therapeutics through clinical validation, then out-licensing or partnering with larger pharmaceutical companies for commercialization. The company may receive milestone payments, upfront payments, royalties, and co-development funding from pharmaceutical partners.

pathiostherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pathios Therapeutics is a clinical-stage biotech developing first-in-class, orally-bioavailable small molecule inhibitors of the acid-sensing G protein-coupled receptor GPR65 to reverse immunosuppressive polarization of immune cells in the tumor microenvironment. Its lead asset PTT-4256 is in a Phase 1/2 clinical trial (RAISIC-1) in patients with advanced solid cancers, with broader pipeline programs targeting neuro-oncology and neurodegenerative diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • GPR65 inhibitor PTT-4256 demonstrated IC50 < 1nM in human macrophages with >500-fold selectivity over related receptors
+3 more records
Product overview1 text field

Pathios Therapeutics is a clinical-stage oncology and immunology company developing first-in-class small molecule inhibitors targeting GPR65, an acid-sensing G protein-coupled receptor. The company's primary product is PTT-4256, an oral, highly potent, and selective GPR65 inhibitor currently in Phase 1/2 clinical trials (RAISIC-1) for advanced solid tumors. The broader GPR65 Inhibitor Program encompasses additional therapeutic candidates being developed for cancer and neurological applications. Founded in 2017 and headquartered in Oxford, UK, the company leverages human genetics-led insights to address immune dysfunction in the tumor microenvironment and other diseases.

Product and service2 records
1PTT-4256
CategoryClinical-stage small molecule drug candidate (oncology)
Description

Internally discovered, orally-bioavailable, highly potent (IC50 < 1 nM in human macrophages) and selective (>500-fold over related receptors) small molecule inhibitor of the acid-sensing GPCR GPR65 for cancer immunotherapy. Currently in Phase 1/2 clinical evaluation (RAISIC-1) in patients with advanced solid tumors, with planned combination expansion modules.

2GPR65 Inhibitor Program
CategoryDrug discovery pipeline / platform programs
Description

Pipeline of proprietary first-in-class small molecule GPR65 inhibitors designed to counteract GPR65-mediated immunosuppressive polarization of immune cells in the acidic tumor microenvironment, and to explore GPR65 inhibition in neuro-oncology and neurodegenerative diseases (Alzheimer's Disease, Vascular Dementia, Parkinson's Disease) using CNS-penetrant compounds.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Collaboration on publication in Cancers journal examining role of GPR65 in renal cell carcinoma. Weatherden team contributed alongside Pathios researchers to the scientific publication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-20
Description

MTM is the drug discovery ecosystem that created and continues to incubate Pathios. Provides operational and R&D support. Tom McCarthy and Kirsty McCarthy created MTM which includes other portfolio companies including ThirtyFiveBio, Melio Bio, Lucia Bio, Curlew Bio, and Grey Wolf Therapeutics.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-09-27
Description

Collaboration on £567K Innovate UK grant to optimize CNS-penetrating GPR65 inhibitors for treating malignant brain tumors. Researchers evaluating optimized compounds in preclinical brain cancer models including human ex vivo co-culture system of glioblastoma.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-03-08
Description

Collaboration on £350K Innovate UK Smart Grant to develop tools for translation of GPR65 inhibitors for treatment-resistant melanoma. Researchers from Department of Oncology at University of Oxford working with Pathios.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-02-06
Description

Strategic drug discovery partnership providing industry-leading expertise in GPCR bioscience and medicinal chemistry. Sygnature invested equity in Pathios alongside providing hit-to-lead programme support, computational chemistry, library design, synthesis, and medium throughput screening capabilities.

6University of Oxford - Department of Oncology
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partnership to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages. Collaborating on developing clinical target engagement biomarkers and bioinformatics techniques.

pathiostherapeutics.com
Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

Partnership with Australian clinical trial sites and contract research organizations for conduct of RAISIC-1 Phase 1/2 clinical trial under Australian TGA Clinical Trial Notification scheme.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pathios Therapeutics

Cancer Immunotherapy / Immuno-Oncology Drug Developmentpathiostherapeutics.com

Pathios Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule inhibitors of the acid-sensing GPCR GPR65 to reverse immunosuppression in solid tumours, with lead asset PTT-4256 in Phase 1/2 trials for advanced solid cancers.

What Pathios Therapeutics does

Pathios Therapeutics is a clinical-stage oncology and immunology company founded in 2017 and headquartered at Milton Park, Oxford, UK. The company develops first-in-class small molecule inhibitors of GPR65, an acid-sensing G protein-coupled receptor that drives immunosuppressive polarization of immune cells in the acidic tumour microenvironment. Its lead asset, PTT-4256, is an orally bioavailable, highly selective GPR65 inhibitor (IC50 < 1 nM in human macrophages, >500-fold selectivity over related receptors) that is being evaluated in the RAISIC-1 Phase 1/2 study in patients with advanced solid tumours in Australia, with first patient dosed in November 2024. The company also pursues CNS-penetrating GPR65 inhibitors for malignant brain tumours and is exploring neurodegenerative indications (Alzheimer's, vascular dementia, Parkinson's) supported by human genetic validation linking GPR65 coding variants to disease.

The company's core technology rests on human-genetics-led target validation (notably the GPR65 I231L coding variant, rs3742704) combined with proprietary small molecule chemistry and a partnership with Sygnature Discovery for GPCR medicinal chemistry. Pathios operates within the Molecule to Medicine (MTM) incubator ecosystem alongside sister companies ThirtyFiveBio, Grey Wolf Therapeutics, Melio Bio, Lucia Bio and Curlew Bio, sharing operational and bioinformatics infrastructure.

Pathios' business model is a licensing-and-partnership biotech model: it advances candidates through clinical proof-of-concept and intends to out-license or co-develop with a major pharmaceutical company for global commercialization. The company has raised approximately US$58M to date, including a $25M Series B in April 2024 that brought in Bristol Myers Squibb as a strategic investor alongside Canaan and Brandon Capital. It is pre-revenue with no commercial products, a sub-10-person team (per firmographic data), and primarily uses scientific conferences (AACR, SITC, ESMO, ASCO) and peer-reviewed publications as its marketing channels ahead of a future partnership transaction.

Pathios Therapeutics firmographics

Firmographics
Name
Pathios Therapeutics
Legal name
Pathios Therapeutics Limited
Website
https://pathiostherapeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Pathios Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule inhibitors of the acid-sensing GPCR GPR65 to reverse immunosuppression in solid tumours, with lead asset PTT-4256 in Phase 1/2 trials for advanced solid cancers.
Ownership category
akta.pro rank

Pathios Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy / Immuno-Oncology Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cancer immunotherapy
  • Small molecule therapeutics
  • GPCR drug discovery
  • Immuno-oncology research
  • Clinical-stage biotechnology

Where Pathios Therapeutics is headquartered

Location

Headquarters

HQ city
Milton
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Pathios Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

  1. Pharmaceutical licensing and partnership: As a clinical-stage biotech, Pathios' revenue model centers on developing novel therapeutics through clinical validation, then out-licensing or partnering with larger pharmaceutical companies for commercialization. The company may receive milestone payments, upfront payments, royalties, and co-development funding from pharmaceutical partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Pathios Therapeutics product offering

Product offering

Core offering

Pathios Therapeutics is a clinical-stage biotech developing first-in-class, orally-bioavailable small molecule inhibitors of the acid-sensing G protein-coupled receptor GPR65 to reverse immunosuppressive polarization of immune cells in the tumor microenvironment. Its lead asset PTT-4256 is in a Phase 1/2 clinical trial (RAISIC-1) in patients with advanced solid cancers, with broader pipeline programs targeting neuro-oncology and neurodegenerative diseases.

Product overview

Pathios Therapeutics is a clinical-stage oncology and immunology company developing first-in-class small molecule inhibitors targeting GPR65, an acid-sensing G protein-coupled receptor. The company's primary product is PTT-4256, an oral, highly potent, and selective GPR65 inhibitor currently in Phase 1/2 clinical trials (RAISIC-1) for advanced solid tumors. The broader GPR65 Inhibitor Program encompasses additional therapeutic candidates being developed for cancer and neurological applications. Founded in 2017 and headquartered in Oxford, UK, the company leverages human genetics-led insights to address immune dysfunction in the tumor microenvironment and other diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • PTT-4256 Internally discovered, orally-bioavailable, highly potent (IC50 < 1 nM in human macrophages) and selective (>500-fold over related receptors) small molecule inhibitor of the acid-sensing GPCR GPR65 for cancer immunotherapy. Currently in Phase 1/2 clinical evaluation (RAISIC-1) in patients with advanced solid tumors, with planned combination expansion modules.
  • GPR65 Inhibitor Program Pipeline of proprietary first-in-class small molecule GPR65 inhibitors designed to counteract GPR65-mediated immunosuppressive polarization of immune cells in the acidic tumor microenvironment, and to explore GPR65 inhibition in neuro-oncology and neurodegenerative diseases (Alzheimer's Disease, Vascular Dementia, Parkinson's Disease) using CNS-penetrant compounds.

Quantifiable outcome

  • GPR65 inhibitor PTT-4256 demonstrated IC50 < 1nM in human macrophages with >500-fold selectivity over related receptors
  • +3 more outcomes

Companies that use Pathios Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Pathios Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pathios Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered secondary and core.

  • WeatherdensecondaryStrategic or Co-development Partner · 16 December 2025Collaboration on publication in Cancers journal examining role of GPR65 in renal cell carcinoma. Weatherden team contributed alongside Pathios researchers to the scientific publication.
  • Molecule to Medicine (MTM)coreStrategic or Co-development Partner · 20 November 2024MTM is the drug discovery ecosystem that created and continues to incubate Pathios. Provides operational and R&D support. Tom McCarthy and Kirsty McCarthy created MTM which includes other portfolio companies including ThirtyFiveBio, Melio Bio, Lucia Bio, Curlew Bio, and Grey Wolf Therapeutics.
  • University of NottinghamsecondaryStrategic or Co-development Partner · 27 September 2023Collaboration on £567K Innovate UK grant to optimize CNS-penetrating GPR65 inhibitors for treating malignant brain tumors. Researchers evaluating optimized compounds in preclinical brain cancer models including human ex vivo co-culture system of glioblastoma.
  • University of OxfordsecondaryStrategic or Co-development Partner · 8 March 2021Collaboration on £350K Innovate UK Smart Grant to develop tools for translation of GPR65 inhibitors for treatment-resistant melanoma. Researchers from Department of Oncology at University of Oxford working with Pathios.
  • Sygnature DiscoverycoreTechnology or Integration · 6 February 2019Strategic drug discovery partnership providing industry-leading expertise in GPCR bioscience and medicinal chemistry. Sygnature invested equity in Pathios alongside providing hit-to-lead programme support, computational chemistry, library design, synthesis, and medium throughput screening capabilities.
  • University of Oxford - Department of OncologysecondaryStrategic or Co-development PartnerPartnership to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages. Collaborating on developing clinical target engagement biomarkers and bioinformatics techniques.
  • Australian Clinical Trial Sites and CROssecondaryImplementation/ SI/ Consulting PartnerPartnership with Australian clinical trial sites and contract research organizations for conduct of RAISIC-1 Phase 1/2 clinical trial under Australian TGA Clinical Trial Notification scheme.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Pathios Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Pathios Therapeutics social profiles

Digital presence

Pathios Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pathios Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Pathios Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pathios Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pathios Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathios Therapeutics

What does Pathios Therapeutics do?

Pathios Therapeutics is a clinical-stage biotech developing first-in-class, orally-bioavailable small molecule inhibitors of the acid-sensing G protein-coupled receptor GPR65 to reverse immunosuppressive polarization of immune cells in the tumor microenvironment. Its lead asset PTT-4256 is in a Phase 1/2 clinical trial (RAISIC-1) in patients with advanced solid cancers, with broader pipeline programs targeting neuro-oncology and neurodegenerative diseases.

Is Pathios Therapeutics a public or private company?

Pathios Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pathios Therapeutics founded?

Pathios Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Pathios Therapeutics based?

Pathios Therapeutics is headquartered in Milton, United Kingdom, in the Europe region.

How does Pathios Therapeutics make money?

One revenue line is on record: pharmaceutical licensing and partnership.

Does Pathios Therapeutics have an API?

No public API is recorded for Pathios Therapeutics.

What industry is Pathios Therapeutics in?

Pathios Therapeutics's product category is Cancer Immunotherapy / Immuno-Oncology Drug Development. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive DirectorPathios Therapeutics Limited announced the appointment of Dr. Jon Wigginton as a non-executive director to its board of directors. Dr. Wigginton brings nearly three decades of clinical oncology experience, including leadership roles at Bristol Myers Squibb, MacroGenics, and Cullinan Oncology, and currently serves as President of R&D at Bright Peak Therapeutics. He will advise the company as it advances its lead development asset PTT-4256, a first-in-class oral small molecule GPR65 antagonist currently being evaluated in the Phase 1/2 RAISIC-1 clinical trial for advanced solid tumours.PR NewswirePathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical OfficerPathios Therapeutics appointed Dr. Sumeet Ambarkhane, M.D. as Chief Medical Officer, a physician with over 20 years of experience in clinical care and drug development across academia and the biopharmaceutical industry. Dr. Ambarkhane will guide the advancement of PTT-4256, the company's first-in-class oral small molecule GPR65 inhibitor currently being evaluated in a first-in-human Phase 1/2 clinical trial in advanced solid cancers. The appointment also supports Pathios' strategy to expand into neuroinflammatory diseases, including Alzheimer's disease and Parkinson's disease, where GPR65 inhibition has shown genetic associations.PatsnapPathios Gains $25M for Immunotherapy Trials in Series B FundingPathios Therapeutics Limited raised $25 million in a Series B funding round, with investments from Bristol Myers Squibb, Canaan, and Brandon Capital. The funds will be used to advance its cancer immunotherapy candidate, PTT-4256, into clinical trials by the end of 2024 and expand its workforce.FinSMEsPathios Therapeutics Raises $25M in First Close of Series B FinancingPathios Therapeutics secured $25 million in the first close of its Series B financing, with participation from Bristol Myers Squibb and existing investors Canaan and Brandon Capital. The company plans to utilize these funds to advance the development of small molecule inhibitors targeting GPR65 for cancer immunotherapy applications.PR NewswirePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into ClinicPathios Therapeutics raised $25 million in a Series B financing, including a strategic investment from Bristol Myers Squibb and support from existing investors. The company will use the proceeds to advance its lead candidate PTT-4256 into human clinical trials in advanced solid cancers by the end of 2024 and expand its leadership team.citybizPathios Therapeutics Raises $25M in Series BPathios Therapeutics Limited has successfully raised $25 million in the first close of its Series B financing, which includes a strategic investment from Bristol Myers Squibb and existing support from investors like Canaan and Brandon Capital. The funding will aid in advancing Pathios’ lead drug candidate PTT-4256 into human clinical trials by the end of 2024, targeting an innovative approach to cancer immunotherapy. The investment reflects confidence in Pathios' unique focus on inhibiting GPR65 to combat immunosuppressive cancer environments.PathiostherapeuticsPathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into ClinicPathios Therapeutics announced the first close of a $25 million Series B financing round, secured by strategic investment from Bristol Myers Squibb and support from existing investors Canaan and Brandon Capital. The company intends to use these proceeds to advance its lead drug candidate, PTT-4256, into human clinical trials for advanced solid cancers by the end of 2024.BrandoncapitalPathios TherapeuticsPathios Therapeutics is developing a first-in-class therapy targeting the GPR65 immune receptor to address cancer, which causes approximately 10 million deaths annually. The company aims to restore immune function by inhibiting this receptor within the acidic tumour microenvironment. This approach offers potential treatment options across multiple cancer types.PathiostherapeuticsInnovateUK Grant to Evaluate Immunotherapy Approach for Brain CancerPathios Therapeutics has been awarded a £567K grant from Innovate UK to fund the optimization and preclinical evaluation of novel GPR65 inhibitors for treating malignant brain tumors. The project is being conducted in collaboration with researchers at the University of Nottingham, focusing on enhancing central nervous system penetration of these compounds.